Glimisave M 1 Tablet PR is a fixed-dose combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg. It is primarily indicated for the management of type 2 diabetes mellitus in patients whose blood glucose levels are inadequately controlled by diet, exercise, and monotherapy. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The combination of these two agents provides complementary mechanisms of action, resulting in improved glycemic control. Glimisave M 1 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including diet modification and regular physical activity. The medication should be taken orally with meals to minimize gastrointestinal side effects commonly associated with Metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoglycemia. Regular monitoring of blood glucose levels, renal function, and periodic assessment of glycemic control is essential during therapy. This combination therapy may reduce the risk of diabetes-related complications by maintaining optimal blood glucose levels.

Dosage & How to Use